Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Lonn, E.
Right arrow Articles by Yusuf, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Lonn, E.
Right arrow Articles by Yusuf, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Mechanisms of cardiovascular risk reduction with ramipril: insights from HOPE and HOPE substudies

E. Lonna,1,2, H.C. Gerstein1,2, M. Smieja1,2,3, J.F.E. Mann4 and S. Yusuf1,2

a Department of Medicine, McMaster University, Ontario, Canada
b Population Health Research Institute, McMaster University, Ontario, Canada
c Pathology and Laboratory Medicine, McMaster University, Ontario, Canada
d Department of Nephrology and Hypertension, Schwabing General Hospital, Ludwig Maximillian University, Munchen, Germany

a Eva Lonn, MD, Hamilton General Hospital, 237 Barton Street East, Hamilton, Ontario, Canada L8L 2X2

Abstract

Angiotensin converting enzyme (ACE) inhibitors decrease angiotensin formation, prevent breakdown of bradykinin, and may also act on other peptides of the renin-angiotensin system. Thus, these agents have many effects that can potentially protect the coronary and peripheral vascularature. Which of these "theoretical" mechanisms account for the clinical benefit observed in The Heart Outcomes Prevention Evaluation (HOPE) trial? While the answer to this question is complex and cannot be fully answered, several potential mechanisms have been explored within HOPE and its substudies. These studies demonstrate that ramipril has potent effects on atherosclerosis progression and plaque stabilization as well as on myocardial structure and function. Ramipril also improves glucose metabolism. These effects are dose-dependent but largely blood pressure independent.

Key Words: ACE inhibitors • atherosclerosis • cariovascular disease • HOPE • ramipril • SECURE


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.